

Report of the Trustees and
Unaudited Financial Statements for the Year Ended 31 December 2024
for
THE BRITISH ASSOCIATION FOR THE STUDY OF
THE LIVER
(A COMPANY LIMITED BY GUARANTEE)

Elsby & Co (Sywell) Ltd
Chartered Accountants
155 Wellingborough Road
Rushden
Northamptonshire
NN10 9TB

THE BRITISH ASSOCIATION FOR THE STUDY OF
THE LIVER

Contents of the Financial Statements
for the year ended 31 DECEMBER 2024

	Page
Report of the Trustees	1 to 5
Independent Examiner's Report	6
Statement of Financial Activities	7
Balance Sheet	8 to 9
Cash Flow Statement	10
Notes to the Cash Flow Statement	11
Notes to the Financial Statements	12 to 18
Detailed Statement of Financial Activities	19 to 20

THE BRITISH ASSOCIATION FOR THE STUDY OF
THE LIVER

Report of the Trustees
for the year ended 31 DECEMBER 2024

The trustees who are also directors of the charity for the purposes of the Companies Act 2006, present their report with the financial statements of the charity for the year ended 31 December 2024. The trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019).

The financial statements have been prepared in accordance with the accounting policies set out in notes to the accounts and comply with the charity's governing document, the Charities Act 2011 and Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland published on 16 July 2014 (as amended by Update Bulletin 1 published on 2 February 2016).

OBJECTIVES AND ACTIVITIES

Objectives and aims

The objectives of the company, as set out in the Memorandum of Association as amended by Special Resolution, are to advance education and awareness in liver disease and disorder, by the provision or the facilitation of research directed towards the development and evaluation of treatment of such disease and disorders. The Trustees confirm that they have referred to the guidance contained in the Charity Commission's guidance on public benefit when reviewing the association's aims and objectives and in planning future activities.

The Trustees carry out these objects by:

- Having educational meetings for medical professionals to attend to further their knowledge and advance education, awareness and research into liver disease.
- Supporting special interest groups to further education of specific areas of liver disease.

To assess success in the reporting period, BASL aims to maintain and increase membership, provide educational events; predominantly the Annual Scientific Meeting. Success is also assessed based on sufficient funds being maintained to allow these activities to take place.

Contribution

The contribution of each member is limited to £1 in the event of a dissolution of the Company.

THE BRITISH ASSOCIATION FOR THE STUDY OF
THE LIVER

Report of the Trustees
for the year ended 31 DECEMBER 2024

ACHIEVEMENT AND PERFORMANCE

Charitable activities

BASL Annual Meeting (incorporating the annual BTLG and BLNA meeting)

The 2024 BASL Annual meeting was held at the Harrogate Convention Centre and proved to be a great success providing interaction and learning opportunities. There were 639 delegates across all three meetings which made an excellent surplus. The Sheila Sherlock prize went to Dr Wenhao Li and Dr Felicity Williams received the Andrew Burroughs Young Investigator award.

BASL Schools

BASL Schools are small group meetings provided free of charge to trainee members in Gastroenterology and Hepatology that deliver structured education and interaction with experts in the field. These help the charity to meet its objectives by committing to improving clinical education and training for tomorrow's Hepatology Consultants, Trainees interested in transplantation and anaesthesia.

These were held as 6 interactive Webinars and one face to face meeting. These proved to be a great success and feedback was excellent.

BASL Xtra

This is an online educational conference and was the second one to be held. This a multi-professional, topic focused educational online event. Attendance and surplus were excellent.

BASL Introduction to Hepatology Day

The meeting was held in London. This was deemed to be a great success and provided a surplus.

BVHG Meetings

No meetings were held for BVHG in 2024.

BASL Basic Science Retreat

This was held in London and made a small surplus. The Foundation for Liver Research organised the event on behalf of BASL. This was very popular and well attended.

Special Interest Groups

BASL provides ongoing administrative support to a number of established Special Interest Groups (SIGs) whose remit is to promote and encourage collaborative research and clinical trials in liver disease.

HCC-UK Annual Meeting

This was held at the Clare College Cambridge. This was very well attended and made a small deficit.

CCA-UK Annual Meeting

This was held at Hallam Conference Centre and made an excellent surplus. Changes are being made for future years to increase attendance.

BAAL

A meeting was not held in 2024.

BHPG Educational Meeting

One meeting was held in November in 2024 and made an excellent surplus.

BASL MDT Educational Webinars

Two webinars were held in 2024, making a small surplus. Three more are planned for 2025.

Secretariat

Secretariat services were provided by Executive Business Support Ltd.

THE BRITISH ASSOCIATION FOR THE STUDY OF
THE LIVER

Report of the Trustees
for the year ended 31 DECEMBER 2024

FINANCIAL REVIEW

Financial position

Detailed finance reports are produced for the Trustees for every governing board meeting. The Trustees aim to achieve a surplus or breakeven for every educational meeting. The results for the year are shown on page 6. The Trustees aim to hold sufficient reserves to support key meetings in the event of potential shortfalls in income. The membership and subscriptions database has been updated and clarified and the charity currently has 1,629 (2023: 1,624) active members. The BASL website continued to provide a good platform for providing news and information as well as serving as an interactive communications and an education hub for members.

The charity managed to achieve income of £647,239 (2023: £533,539) during the year.

Cash reserves have increased to £334,084 (2023: £261,210) due to the charity continuing to hold some events on a virtual basis as well as face to face. This is mainly due to increased sponsorship income from Pharmaceutical companies. Of these cash reserves, £22,377 is held in restricted funds (2023: £22,377).

To ensure a balanced picture of the charity's progress against its objectives, sufficient funds are maintained to allow the desired educational events held to continue to take place. The Trustees believe that the charity has sufficient reserves to continue and hopes to achieve a greater surplus in 2025 with the aim of continuing to hold events on a face to face basis, as well as some on a virtual basis.

The key performance indicators to explain outputs achieved by activities are the level and numbers of members increasing, as well as maintaining delegate members at educational events. On both of these indicators, the charity has performed well in the year.

Reserves policy

Reserves are needed as sponsorship by Pharmaceutical Companies of educational events, which are one of the key objectives of BASL, can drop suddenly depending on the current focus of the Pharmaceutical Companies. As stated in the Articles of Association: The Association will aim to retain sufficient capital funds in reserve to permit it to conduct its activities as defined by the Governing Board for a period of two years in the absence of any income over this period.

At the balance sheet date, the charity had free reserves of £319,313 (2023: £195,256). Of these reserves, £22,377 is held in restricted funds (2023: £23,377) and £296,936 is held in unrestricted funds (2023: £172,878).

The charity always hopes to retain reserves in unrestricted funds to cover 24 months operational costs. At the end of the accounting period, free reserves had increased but continue to remain below the 24 month target. However, the charity anticipates that free reserves will continue to grow over the coming years and will return to former levels. The Trustees are confident that the charity retains sufficient funds to continue operating and furthering its charitable purpose.

FUTURE DEVELOPMENTS

The Trustees aim to continue to provide educational meetings and other member benefits in accordance with the objectives of the Charity. The experience of the pandemic has resulted in the ability to run meetings on a virtual basis to ensure events still take place, making meetings accessible to members and meaning external risk factors are more manageable.

The Governing Board commenced discussions and plans for a new upgraded website providing increased functionality, reporting and member experience for 2025. The final decision was to be made at a Governing Board meeting following the annual meeting, which would give an indication of the financial position for the year.

STRUCTURE, GOVERNANCE AND MANAGEMENT

Governing document

The charity is controlled by its governing document, a deed of trust, and constitutes a limited company, limited by guarantee, as defined by the Companies Act 2006.

THE BRITISH ASSOCIATION FOR THE STUDY OF
THE LIVER

Report of the Trustees
for the year ended 31 DECEMBER 2024

STRUCTURE, GOVERNANCE AND MANAGEMENT

Induction and training of new trustees

Newly elected Trustees attend quarterly meetings with the Chairperson and the governing board to observe the provision of services to members. They are also given guidance which include an outline of their role and a handover from the outgoing Trustee.

The charity makes decisions through its governing board. Policies and procedures for induction and training of Trustees is supported by the current and outgoing Trustees.

REFERENCE AND ADMINISTRATIVE DETAILS

Registered Company number

05017662 (England and Wales)

Registered Charity number

1106320

Registered office

St Chad's Road
Lichfield
Staffordshire
WS13 6TJ

Trustees

Dr T J S Cross Consultant Hepatologist
Dr T J Kendall Senior Clinical Fellow In Pathology
Dr I A C Rowe University Clinical Academic Fellow
Dr V Snowdon Consultant Hepatologist
Ms M B Clayton Lecturer In Liver Care
Professor M E Cramp Consultant Hepatologist
Dr A M Elsharkawy Consultant Hepatologist
Professor R Mookerjee Professor of Translational Hepatology
Dr M Allison Consultant Hepatologist
Dr S Chokshi Acting Director & Chief Scientific Offic
Dr O A A Elshaarawy
Professor P Kennedy Consultant Hepatologist and Gastroentero
Mr J A Richard Doctor
Dr L Vine Consultant Hepatologist (appointed 1.11.24)
Dr V Patel Consultant Hepatologist (appointed 1.11.24)
Dr D Joshi Transplant Hepatologist&HPB Endoscopist (appointed 1.11.24)

Independent Examiner


Carl Elsby ACA
Elsby & Co (Sywell) Ltd
Chartered Accountants
155 Wellingborough Road
Rushden
Northamptonshire
NN10 9TB

**THE BRITISH ASSOCIATION FOR THE STUDY OF
THE LIVER**

**Report of the Trustees
for the year ended 31 DECEMBER 2024**

This report has been prepared in accordance with the special provisions of Part 15 of the Companies Act 2006 relating to small companies.

Approved by order of the board of trustees on 30 July 2025 and signed on its behalf by:


.....
Dr A M Elsharkawy - Trustee

Independent Examiner's Report to the Trustees of
The British Association for the Study of
the Liver

Independent examiner's report to the trustees of The British Association for the Study of the Liver ('the Company')

I report to the charity trustees on my examination of the accounts of the Company for the year ended 31 December 2024.

Responsibilities and basis of report

As the charity's trustees of the Company (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').

Having satisfied myself that the accounts of the Company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity's accounts as carried out under Section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under Section 145(5) (b) of the 2011 Act.

Independent examiner's statement

Since your charity's gross income exceeded £250,000 your examiner must be a member of a listed body. I can confirm that I am qualified to undertake the examination because I am a member of the Institute of Chartered Accountants in England and Wales, which is one of the listed bodies.

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe:

1. accounting records were not kept in respect of the Company as required by Section 386 of the 2006 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the accounting requirements of Section 396 of the 2006 Act other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination; or
4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities (applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.



Carl Elsby ACA

Elsby & Co (Sywell) Ltd
Chartered Accountants
155 Wellingborough Road
Rushden
Northamptonshire
NN10 9TB

Date: 15/07/2025

**THE BRITISH ASSOCIATION FOR THE STUDY OF
THE LIVER**

**Statement of Financial Activities
for the year ended 31 DECEMBER 2024**

	Notes	Unrestricted funds £	Restricted funds £	2024 Total funds £	2023 Total funds £
INCOME AND ENDOWMENTS FROM					
Membership subscriptions	3	110,935	-	110,935	116,383
Conference fees & sponsorship income	4	528,508	-	528,508	413,049
Interest receivable	5	3,029	-	3,029	4,107
Legacies and donations		4,767	-	4,767	-
Total		<u>647,239</u>	<u>-</u>	<u>647,239</u>	<u>533,539</u>
EXPENDITURE ON					
Conference costs					
Direct conference costs	6	310,283	-	310,283	287,534
Other associated conference costs	7	207,794	-	207,794	189,113
		<u>518,077</u>	<u>-</u>	<u>518,077</u>	<u>476,647</u>
Other		<u>5,105</u>	<u>-</u>	<u>5,105</u>	<u>9,014</u>
Total		<u>523,182</u>	<u>-</u>	<u>523,182</u>	<u>485,661</u>
NET INCOME		124,057	-	124,057	47,878
RECONCILIATION OF FUNDS					
Total funds brought forward		172,879	22,377	195,256	147,378
TOTAL FUNDS CARRIED FORWARD		<u>296,936</u>	<u>22,377</u>	<u>319,313</u>	<u>195,256</u>

CONTINUING OPERATIONS

All income and expenditure has arisen from continuing activities.

The notes form part of these financial statements

THE BRITISH ASSOCIATION FOR THE STUDY OF
THE LIVER

Balance Sheet
31 DECEMBER 2024

	Notes	Unrestricted funds £	Restricted funds £	2024 Total funds £	2023 Total funds £
FIXED ASSETS					
Investments	12	1	-	1	1
CURRENT ASSETS					
Debtors: amounts falling due within one year	13	53,331	-	53,331	40,753
Cash at bank		311,707	22,377	334,084	261,210
		<u>365,038</u>	<u>22,377</u>	<u>387,415</u>	<u>301,963</u>
CREDITORS					
Amounts falling due within one year	14	(39,796)	-	(39,796)	(69,926)
		<u>325,242</u>	<u>22,377</u>	<u>347,619</u>	<u>232,037</u>
NET CURRENT ASSETS					
		325,242	22,377	347,620	232,038
TOTAL ASSETS LESS CURRENT LIABILITIES					
		325,243	22,377	347,620	232,038
CREDITORS					
Amounts falling due after more than one year	15	(28,307)	-	(28,307)	(36,782)
		<u>296,936</u>	<u>22,377</u>	<u>319,313</u>	<u>195,256</u>
NET ASSETS					
		296,936	22,377	319,313	195,256
FUNDS	16				
Unrestricted funds:					
General fund				296,936	172,879
Restricted funds:					
BASL nurses fund				6,627	6,627
CCA UK Neil Blenkinsop donation for research only				15,750	15,750
				<u>22,377</u>	<u>22,377</u>
TOTAL FUNDS				<u>319,313</u>	<u>195,256</u>

The charitable company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 December 2024.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 December 2024 in accordance with Section 476 of the Companies Act 2006.

The notes form part of these financial statements

THE BRITISH ASSOCIATION FOR THE STUDY OF
THE LIVER


Balance Sheet - continued
31 DECEMBER 2024

The trustees acknowledge their responsibilities for

- (a) ensuring that the charitable company keeps accounting records that comply with Sections 386 and 387 of the Companies Act 2006 and
- (b) preparing financial statements which give a true and fair view of the state of affairs of the charitable company as at the end of each financial year and of its surplus or deficit for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the charitable company.

These financial statements have been prepared in accordance with the provisions applicable to charitable companies subject to the small companies regime.

The financial statements were approved by the Board of Trustees and authorised for issue on 31st Dec 2024 and were signed on its behalf by:


.....
Dr A M Elsharkawy - Trustee

**THE BRITISH ASSOCIATION FOR THE STUDY OF
THE LIVER**

**Cash Flow Statement
for the year ended 31 DECEMBER 2024**

	Notes	2024 £	2023 £
Cash flows from operating activities			
Cash generated from operations	1	69,845	50,366
Net cash provided by operating activities		69,845	50,366
Cash flows from investing activities			
Interest received		3,029	4,107
Net cash provided by investing activities		3,029	4,107
Change in cash and cash equivalents in the reporting period		72,874	54,473
Cash and cash equivalents at the beginning of the reporting period		261,210	206,737
Cash and cash equivalents at the end of the reporting period		334,084	261,210

The notes form part of these financial statements

**THE BRITISH ASSOCIATION FOR THE STUDY OF
THE LIVER**

**Notes to the Cash Flow Statement
for the year ended 31 DECEMBER 2024**

1. RECONCILIATION OF NET INCOME TO NET CASH FLOW FROM OPERATING ACTIVITIES

	2024 £	2023 £
Net income for the reporting period (as per the Statement of Financial Activities)	124,057	47,878
Adjustments for:		
Interest received	(3,029)	(4,107)
Increase in debtors	(12,578)	(22,860)
(Decrease)/increase in creditors	(38,605)	29,455
	<hr/>	<hr/>
Net cash provided by operations	<u>69,845</u>	<u>50,366</u>

2. ANALYSIS OF CHANGES IN NET FUNDS

	At 1.1.24 £	Cash flow £	At 31.12.24 £
Net cash			
Cash at bank	261,210	72,874	334,084
	<hr/>	<hr/>	<hr/>
	261,210	72,874	334,084
	<hr/>	<hr/>	<hr/>
Total	<u>261,210</u>	<u>72,874</u>	<u>334,084</u>

The notes form part of these financial statements

THE BRITISH ASSOCIATION FOR THE STUDY OF
THE LIVER

Notes to the Financial Statements
for the year ended 31 DECEMBER 2024

1. ACCOUNTING POLICIES

General information

The charity is a private company limited by guarantee, registered in England and Wales and a registered charity in England and Wales. The address of the registered office is Executive Business Support, Davidson Road, Lichfield, Staffordshire, England, WS14 9DZ.

Basis of preparing the financial statements

The financial statements of the charitable company, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)', Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006. The financial statements have been prepared under the historical cost convention, with the exception of investments which are included at market value.

The presentational currency of BASL is considered to be pounds sterling and the financial statements are rounded to the nearest pound.

Incoming resources

All income is recognised in the Statement of Financial Activities once the charity has entitlement to the funds, it is probable that the income will be received and the amount can be measured reliably.

Income received for a specific restricted purpose is credited to a separate restricted fund which is shown in a note to the financial statements. Total incoming resources credited to restricted funds are disclosed on the statement of financial activities which also shows incoming resources in respect of unrestricted funds.

Conference income represents fees and sponsorship received in respect of conference's organised in pursuit of the company's charitable objectives.

Income associated with conferences of future accounting periods is treated as deferred income.

Resources expended

Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources. Resources expended are included in the statement of financial activities on an accrual basis exclusive of VAT. All irrecoverable VAT is charged against the category of resources expended for which it was incurred.

Taxation

The activities of the charity are exempt from Corporation Tax under Section 505 of the Income and Corporation Taxes Act 1988 to the extent that they are applied to the organisation's charitable objects.

Fund accounting

Unrestricted funds are donations and other incoming resources received or generated for the general charitable purposes of the charity.

Within unrestricted funds are designated funds. The nature of each of the designated funds is referred to within the report of the trustees.

Restricted funds can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes.

THE BRITISH ASSOCIATION FOR THE STUDY OF
THE LIVER

Notes to the Financial Statements - continued
for the year ended 31 DECEMBER 2024

1. ACCOUNTING POLICIES - continued

Debtors and creditors

Short term debtors are measured at transaction price (which is usually the invoice price), less any impairment losses for bad and doubtful debts. Loans and other financial assets are initially recognised at transaction price including any transaction costs and subsequently measured at amortised cost determined using the effective interest method, less any impairment losses for bad and doubtful debts.

Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs and subsequently measured at amortised cost determined using the effective interest method.

Cash and cash equivalents

Cash and cash equivalents include cash in hand and deposits held at call with banks.

2. CRITICAL ACCOUNTING JUDGEMENTS AND KEY SOURCES OF ESTIMATION UNCERTAINTY

In preparing the financial statements it is necessary to make certain judgements, estimates and assumptions that affect the amounts recognised in the financial statements.

In the view of the trustees in applying the accounting policies adopted, no judgements were required that have a significant effect on the amounts recognised in the financial statements nor do any estimates or assumptions made carry a significant risk of material adjustment in the next financial year.

3. MEMBERSHIP SUBSCRIPTIONS

	2024	2023
	£	£
Grants	-	12,729
Subscriptions	110,935	103,654
	<hr/>	<hr/>
	110,935	116,383
	<hr/>	<hr/>

Grants receivable are credited to the Statement of Financial Activities (SOFA) in the year for which they are received. Deferred income represents amounts received for future periods and is released to incoming resources in the period for which it has been received.

4. CONFERENCE FEES & SPONSORSHIP INCOME

	2024	2023
	£	£
Conference income	528,508	413,049
	<hr/>	<hr/>

THE BRITISH ASSOCIATION FOR THE STUDY OF
THE LIVER

Notes to the Financial Statements - continued
for the year ended 31 DECEMBER 2024

5. INTEREST RECEIVABLE		
	2024	2023
	£	£
Interest receivable	3,029	4,107
	<u> </u>	<u> </u>
6. DIRECT CONFERENCE COSTS		
	2024	2023
	£	£
Annual conference costs	291,183	274,284
Support to Non-BASL activities	19,100	13,250
	<u> </u>	<u> </u>
	310,283	287,534
	<u> </u>	<u> </u>
7. OTHER ASSOCIATED CONFERENCE COSTS		
	2024	2023
	£	£
Travel & hotels	2,950	12,511
Artwork/design & print	230	4,216
CPD application	-	956
Bank charges	5,251	5,282
Website	6,489	4,408
Secretarial support costs	7,918	8,044
EBS Costs	186,865	170,635
Partial exemption input VAT	(1,909)	(16,939)
	<u> </u>	<u> </u>
	207,794	189,113
	<u> </u>	<u> </u>
8. SUPPORT COSTS		
		Governance costs
		£
Other resources expended		5,105
		<u> </u>
9. NET INCOME/(EXPENDITURE)		
Net income/(expenditure) is stated after charging/(crediting):		
	2024	2023
	£	£
Accountancy fees	5,105	5,012
	<u> </u>	<u> </u>

THE BRITISH ASSOCIATION FOR THE STUDY OF
THE LIVER

Notes to the Financial Statements - continued
for the year ended 31 DECEMBER 2024

10. TRUSTEES' REMUNERATION AND BENEFITS

No trustees received any remuneration during the current or prior year.

Trustees' expenses

Travel and speaker expenses totalling £635.29 (2023; £525.36) were reimbursed to 2 (2023; 4) trustees during the year.

11. COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES

	Unrestricted funds £	Restricted funds £	Total funds £
INCOME AND ENDOWMENTS FROM			
Membership subscriptions	116,383	-	116,383
Conference fees & sponsorship income	413,049	-	413,049
Interest receivable	4,107	-	4,107
Total	<u>533,539</u>	<u>-</u>	<u>533,539</u>
EXPENDITURE ON			
Conference costs			
Direct conference costs	287,534	-	287,534
Other associated conference costs	189,113	-	189,113
	<u>476,647</u>	<u>-</u>	<u>476,647</u>
Other	9,014	-	9,014
Total	<u>485,661</u>	<u>-</u>	<u>485,661</u>
NET INCOME	47,878	-	47,878
RECONCILIATION OF FUNDS			
Total funds brought forward	125,001	22,377	147,378
TOTAL FUNDS CARRIED FORWARD	<u>172,879</u>	<u>22,377</u>	<u>195,256</u>

**THE BRITISH ASSOCIATION FOR THE STUDY OF
THE LIVER**

**Notes to the Financial Statements - continued
for the year ended 31 DECEMBER 2024**

12. FIXED ASSET INVESTMENTS

	Unlisted investments £
MARKET VALUE	
At 1 January 2024 and 31 December 2024	1
	<hr/>
NET BOOK VALUE	
At 31 December 2024	1
	<hr/>
At 31 December 2023	1
	<hr/>

There were no investment assets outside the UK.

13. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2024	2023
	£	£
Trade debtors	16,285	32,418
VAT	3,606	-
Prepayments	33,440	8,335
	<hr/>	<hr/>
	53,331	40,753
	<hr/>	<hr/>

14. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

Deferred income

	2024	2023
	£	£
Deferred income at 1 January 2024	23,780	23,000
Resources deferred during the year	5,820	23,780
Amounts released from prior year	(23,780)	(23,000)
	<hr/>	<hr/>
Deferred income at 31 December 2024	5,820	23,000
	<hr/>	<hr/>

Deferred income relates to income received in the year specifically relating to performance conditions to be met in the following year.

**THE BRITISH ASSOCIATION FOR THE STUDY OF
THE LIVER**

**Notes to the Financial Statements - continued
for the year ended 31 DECEMBER 2024**

15. CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE YEAR

	2024	2023
	£	£
Bursary Fund - support for members to attend meetings	15,828	24,303
BLNA restricted fund	12,479	12,479
	<u>28,307</u>	<u>36,782</u>

16. MOVEMENT IN FUNDS

	At 1.1.24	Net movement in funds	At 31.12.24
	£	£	£
Unrestricted funds			
General fund	172,879	124,057	296,936
Restricted funds			
BASL nurses fund	6,627	-	6,627
CCA UK Neil Blenkinsop donation for research only	15,750	-	15,750
	<u>22,377</u>	<u>-</u>	<u>22,377</u>
TOTAL FUNDS	<u>195,256</u>	<u>124,057</u>	<u>319,313</u>

Net movement in funds, included in the above are as follows:

	Incoming resources	Resources expended	Movement in funds
	£	£	£
Unrestricted funds			
General fund	647,239	(523,182)	124,057
TOTAL FUNDS	<u>647,239</u>	<u>(523,182)</u>	<u>124,057</u>

**THE BRITISH ASSOCIATION FOR THE STUDY OF
THE LIVER**

**Notes to the Financial Statements - continued
for the year ended 31 DECEMBER 2024**

16. MOVEMENT IN FUNDS - continued

Comparatives for movement in funds

	At 1.1.23 £	Net movement in funds £	At 31.12.23 £
Unrestricted funds			
General fund	125,001	47,878	172,879
Restricted funds			
BASL nurses fund	6,627	-	6,627
CCA UK Neil Blenkinsop donation for research only	15,750	-	15,750
	<u>22,377</u>	<u>-</u>	<u>22,377</u>
TOTAL FUNDS	<u>147,378</u>	<u>47,878</u>	<u>195,256</u>

Comparative net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
Unrestricted funds			
General fund	533,539	(485,661)	47,878
	<u>533,539</u>	<u>(485,661)</u>	<u>47,878</u>
TOTAL FUNDS	<u>533,539</u>	<u>(485,661)</u>	<u>47,878</u>

17. RELATED PARTY DISCLOSURES

There were no related party transactions for the year ended 31 December 2024.

THE BRITISH ASSOCIATION FOR THE STUDY OF
THE LIVER

Detailed Statement of Financial Activities
for the year ended 31 DECEMBER 2024

	2024 £	2023 £
INCOME AND ENDOWMENTS		
Membership subscriptions		
Grants	-	12,729
Subscriptions	110,935	103,654
	<hr/> 110,935	<hr/> 116,383
Conference fees & sponsorship income		
Conference income	528,508	413,049
Interest receivable		
Interest receivable	3,029	4,107
Legacies and donations		
Legacy donations	500	-
Donations	4,267	-
	<hr/> 4,767	<hr/> -
Total incoming resources	647,239	533,539
EXPENDITURE		
Direct conference costs		
Annual conference costs	291,183	274,284
Support to Non-BASL activities	19,100	13,250
	<hr/> 310,283	<hr/> 287,534
Other associated conference costs		
Travel & hotels	2,950	12,511
Artwork/design & print	230	4,216
CPD application	-	956
Bank charges	5,251	5,282
Website	6,489	4,408
Secretarial support costs	7,918	8,044
EBS Costs	186,865	170,635
Partial exemption input VAT	(1,909)	(16,939)
	<hr/> 207,794	<hr/> 189,113
Support costs		
Governance costs		
Accountancy fees	5,105	5,012
Carried forward	5,105	5,012

This page does not form part of the statutory financial statements

**THE BRITISH ASSOCIATION FOR THE STUDY OF
THE LIVER**

**Detailed Statement of Financial Activities
for the year ended 31 DECEMBER 2024**

	2024 £	2023 £
Governance costs		
Brought forward	5,105	5,012
Other legal and professional	-	4,002
	<hr/> 5,105	<hr/> 9,014
Total resources expended	<hr/> 523,182	<hr/> 485,661
Net income	<hr/> <hr/> 124,057	<hr/> <hr/> 47,878

This page does not form part of the statutory financial statements